Tag: DLL3-targeted therapy

Home / DLL3-targeted therapy

Categories

Tarlatamab-dlle is granted accelerated approval by FDA for extensive stage small cell lung cancer

May 2024: Tarlatamab-dlle (Imdelltra, Amgen, Inc.) has received fast approval from the Food and Drug Administration for the treatment of extensive stage small cell lung cancer (ES-SCLC) in patients wh...
dll3-targeted-therapy

We Are Online! Chat With Us!
Scan the code